ENDRA Life Sciences Inc. Overview
Pro stress-test →ENDRA Life Sciences is a biotechnology company developing medical imaging technology based on the thermoacoustic effect that improves the sensitivity and specificity of clinical ultrasound. The company is focused on early detection of liver disease through its proprietary TAEUS® technology, which is now CE-marked for sale in Europe. The technology is non-invasive and costs 50x less than MRI.
Strategic Profile
Pro stress-test →ENDRA is developing a next-generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI—at a fraction of the cost, and at the point-of-care. The company engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. In October 2025, the company closed a private investment in public equity (PIPE) financing, raising approximately $4.9 million in gross proceeds, with the potential for up to an additional $9.5 million from warrant exercises.
Competitive Landscape
Pro stress-test →ENDRA operates in the medical imaging and diagnostic ultrasound space, competing against established MRI and CT vendors as well as alternative liver assessment methods. The company's primary competitive advantage is cost efficiency (50x cheaper than MRI) and non-invasive point-of-care deployment. Direct competitors would include ultrasound device manufacturers like GE Healthcare, Philips, and Siemens, as well as companies developing alternative metabolic biomarker technologies for liver disease detection.
Industry Context
ENDRA Life Sciences Inc. operates in Medical imaging devices and diagnostic ultrasound.
Key facts
Founded: 2007 · Headquarters: Ann Arbor, US · Employees: 10 · Market cap: $8.43M